Personalized Medicine: A Canadian Collaborative

Perspective Munich, May 27 2013

Etienne Richer, PhD CIHR Institute of Genetics

As defined by the Personalized Medicine Working Group

(Health Canada):

Personalized medicine refers to the tailoring of preventative,

diagnostic or therapeutic interventions to the characteristics

of an individual or population.

It does not mean the creation of health interventions

targeted directly to an individual, but rather that the scientific

advancements that underpin personalized medicine provide

the ability to classify individuals into sub-populations based

on their susceptibility to a disease, or response to a specific

treatment.

This can allow for prevention/intervention strategies

and earlier and/or targeted interventions to improve

health outcomes.

Personalized “Stratified” Medicine/Health

CIHR and its Institutes

Enhance health outcomes through patient stratification approaches by integrating evidence-based medicine and precision

diagnostics into clinical practice

Develop and translate discoveries

Biomarkers, targets and

genomic signatures

Diagnostics and innovative devices

(imaging and point of care devices) for

clinical use

Support policy and practice

Improve the evidence base on how to assess and eventually integrate innovative diagnostics

and therapeutic approaches into practice

Personalized Medicine Initiative

Canadian Personalized Medicine

Stakeholder Map

Federal

Patient / Professional

Groups

Provinces & Territories Industry

Research

CIHR/ NSERC/

Genome Canada

Research Priorities

National Lab Standards

Product R&D

PMPRB Product

Submissions

Surveillance

CADTH

Health Canada

PHAC

National Policy Interests

Provincial & Territorial Research

Formulary Discussions

Provincial & Territorial Lab Standards

T. Ryan Sigouin, Health Canada adapted by Inga Murawski CIHR-ICR and Etienne Richer CIHR-IG

Healthcare Priorities

INESSS

Building a National Framework

• CIHR-Genome Canada Funding Opportunities

• Pediatric cancer consortium

• Rare Disease Consortium (FORGE) Evidence

• Health Canada and provincial regulators engagement

• International Policies for Research (IRDiRC)

Regulatory and Policy Challenge

• SPOR networks-clinical trials

• Networking initiatives in Canada

• National Framework/Consortium National Structure

• Community-Based Primary Health Care Innovation Teams - CIHR Signature Initiative

• Public Outreach Outreach

• Data Harmonization/eHealth data

• Computational Biology

• National Asset Map Data

2010 Advancing Technology Innovation

through Discovery Program ($6.5M)

Finding of Rare Disease Genes in Canada (FORGE) • Goal: To rapidly identify disease-causing genes

responsible for rare genetic disorders that affect children in

Canada

• 132 rare disorders studied to date

The Canadian Pediatric Cancer Genome Consortium • Goal: To rapidly identify cancer-causing genes, improve

survival, and reduce long-term consequences for children

with brain, bone and blood cancers

Evidence

2012 Genomics and Personalized

Health $71 M ($142 M)

Large Scale Research Projects ($5 + $5 M)

• Demonstrate how omics-based research and technology can

contribute to a more evidence-based approach to health

• Applications must demonstrate high potential for attaining

eventual clinical utility and/or practical applicability

Large Scale GE3LS Projects

• Including genomics: utility, clinical and comparative

effectiveness

Results will be known Spring 2013

17 teams funded

Evidence

Multidisciplinary Research Teams Funded in 2012 ($29 M)

Evidence

Emerging Team Grant – Rare Diseases ($17 M) • To enhance our understanding of the fundamental biology of

these diseases, foster the application of that knowledge to the

clinic or to populations (group 1), and/or address major health

services/policy/economic/ethical, legal or social issues

challenges (group 2)

• 5 teams funded (group 1); 4 teams funded (group 2)

Childhood Cancer – Late Effects of Treatment ( $12 M) • Multidisciplinary teams address major late effects of cancer

treatment, through stratification, reducing toxicity leading to

enhanced survivorship, Quality of Life

• 4 Teams funded

2012 Bioinformatics and

Computational Biology ($11 M)

Data

Small-Scale Innovative Projects ($250K for 2 years)

Large-Scale Applied Projects ($500K for 3 years)

• Goal: to support the development (and access) of next

generation Bioinformatics and Computational Biology tools

and methodologies that will be required by the research

community to deal with the influx of large amounts of data

produced by modern genomics technologies

Engagement and Support Structure

Engage Health Canada and Provincial Regulators

• Organize workshops and meetings (May 2011, January 2012,

March 2013)

Regulatory and

Policy Challenge

National

Structure

Develop National Infrastructure and Services

• By continuing to develop a national infrastructure and services,

including biobanks, networks, clinical trials, portals

Global Reach – Personalized Medicine

Rare Diseases Cancer Personalized

Medicine

• If only 1 Priority: Develop an innovative clinical trial design

framework/specialized support unit

• We are open for business…

• Consider Canada (CIHR) as a friend who wants to play…

Conclusions

Thank You

Dr. Morag Park, Scientific Director of CIHR’s Institute of Cancer Research mpark.ic-icr@mcgill.ca Dr. Inga Murawski, Associate, Strategic Initiatives Inga.murawski@mcgill.ca

Dr. Paul Lasko, Scientific Director of CIHR’s Institute of Genetics Paul.lasko@mcgill.ca Dr. Etienne Richer, Assistant Director Etienne.richer@mcgill.ca